EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head...| www.sanofi.com
By Brian Buntz | June 23, 2025| Drug Discovery and Development
By Dr. Qigan Cheng | August 18, 2025| Drug Discovery and Development
By Vinita Navadgi | October 3, 2025| Drug Discovery and Development
Sanofi and Regeneron have announced that the monoclonal antibody outperformed Xolair (omalizumab) on all primary and secondary efficacy endpoints in a phase 4 study focused on patients with chronic rhinosinusitis.| Drug Discovery and Development
Just over three-quarters of patients receiving Sanofi and Regeneron’s Dupixent achieved at least a 75% improvement in disease severity.| Drug Discovery and Development
By Brian Buntz | April 30, 2025| Drug Discovery and Development
